Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.26B 185M 162M 150M 139M 264M 17.69B 267M 1.79B 697M 8.68B 696M 681M 30.1B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 1.04B 153M 134M 123M 114M 217M 14.56B 220M 1.47B 574M 7.15B 573M 561M 24.79B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.67%
Yield 2024 *
-
Yield 2025 -
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-16 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-08 Shanghai Rightongene Biotechnology's boards elects chairman RE
25-08-28 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
25-02-19 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
25-02-17 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
25-01-02 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
24-10-29 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
24-10-28 Rightongene Biotechnology's Chairman, Vice General Managers Arrested for Fraud Suspicion; Shares Down 4% MT
1 day+1.65%
1 week+12.30%
Current month+10.50%
1 month-5.39%
3 months-16.47%
6 months-21.38%
Current year-13.36%
1 week 20.21
Extreme 20.21
23.34
1 month 19.32
Extreme 19.32
24.5
Current year 19.32
Extreme 19.32
33.27
1 year 19.32
Extreme 19.32
36
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
103.01
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 2024-07-21
Director of Finance/CFO 34 2025-01-26
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 53 2023-08-23
Chairman 69 2024-07-21
Director/Board Member 41 2019-05-12
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%+12.30%-14.97%-42.10% 185M
+0.50%+9.81%+234.30%+364.30% 22.39B
+1.73%+2.98%-40.65%-22.17% 9.37B
-6.43%-6.17%+27.85%+26.30% 6.69B
-2.68%-2.78%-32.89% - 5.03B
-7.52%-4.72%-24.62%-33.28% 4.74B
+2.54%+7.67%+207.46%-24.49% 5.08B
-2.22%+1.30%-23.12%-24.98% 4.25B
-4.73%-5.28%+73.33%+82.47% 3.9B
+0.35%+4.11%-17.16%-39.64% 2.62B
Average -1.68%+1.33%+38.95%+31.82% 6.42B
Weighted average by Cap. -1.22%+2.63%+92.80%+134.19%

Financials

2024 2025
Net sales 242M 35.66M 31.23M 28.77M 26.7M 50.71M 3.4B 51.39M 344M 134M 1.67B 134M 131M 5.79B 177M 26.09M 22.85M 21.05M 19.53M 37.1M 2.49B 37.6M 252M 98.04M 1.22B 97.98M 95.83M 4.24B
Net income -15.76M -2.32M -2.03M -1.87M -1.74M -3.3M -221M -3.34M -22.4M -8.72M -109M -8.71M -8.52M -377M -50.38M -7.41M -6.49M -5.98M -5.55M -10.54M -707M -10.69M -71.59M -27.86M -347M -27.84M -27.23M -1.2B
Net Debt -210M -30.95M -27.11M -24.97M -23.18M -44.01M -2.95B -44.6M -299M -116M -1.45B -116M -114M -5.02B -223M -32.75M -28.68M -26.42M -24.52M -46.56M -3.12B -47.19M -316M -123M -1.53B -123M -120M -5.32B
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company principally engaged in the research and development, production and sales of in-vitro diagnostic products, as well as the provision of scientific research and testing services. The Company's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The Company mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The Company also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The Company mainly conducts its businesses within domestic market.
Employees
336
Date Price Change Volume
26-07-06 CN¥22.83 +1.65% 1,249,972
26-07-03 CN¥22.46 +3.26% 1,556,709
26-07-02 CN¥21.75 +2.30% 1,748,711
26-07-01 CN¥21.26 +2.90% 1,056,951
26-06-30 CN¥20.66 +1.62% 1,131,632

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688217 Stock